GRI

US3622AW1069

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-15 pm EDT			5-day change	1st Jan Change
0.4007 ^USD	-1.18%		+2.72%	-94.02%

Apr. 16	GRI Bio Receives South Korea Patent for Liver Inflammatory Condition Treatments	MT
2023	Vallon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Vallon Pharmaceuticals, Inc. Announces Appointment of Meenu Karson to Board of Directors

February 28, 2022 at 04:05 pm EST

Vallon Pharmaceuticals, Inc. announced the appointment of Meenu Karson to its Board of Directors. Most recently, Ms. Karson served as the President and CEO of Proteostasis Therapeutics, Inc.

Latest news about GRI BIOPAR

GRI Bio Receives South Korea Patent for Liver Inflammatory Condition Treatments	Apr. 16	MT
Vallon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	Dec. 15	CI
Vallon Pharmaceuticals, GRI Bio Complete Merger	23-04-21	MT
Vallon Pharmaceuticals' Stockholders Approve Merger With GRI Bio, Reverse Stock Split	23-04-21	MT
Vallon Pharmaceuticals, Inc.(NasdaqCM:VLON) dropped from NASDAQ Composite Index	23-04-21	CI
GRI Bio, Inc. completed the acquisition of Vallon Pharmaceuticals, Inc. from group of shareholders in a reverse merger transaction.	23-04-20	CI
Vallon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-24	CI
Vallon Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-02-23	CI
Top Premarket Gainers	23-02-15	MT
Top Premarket Gainers	23-02-13	MT
Sector Update: Healthcare Stocks Mixed Premarket Friday	22-12-30	MT
Vallon Pharmaceuticals Gets Notice of Delisting From Nasdaq; Plans Reverse Stock Split	22-12-29	MT
Sector Update: Health Care Stocks Stage Small Recovery Late	22-12-14	MT
Sector Update: Health Care Stocks Posting Moderate Gains	22-12-14	MT
Sector Update: Health Care	22-12-14	MT
Stocks Remain Relatively Flat as Investors Wait for Fed Rate-Hike Move	22-12-14	MT
Vallon Pharmaceuticals, GRI Bio to Merge in All-Stock Deal, Shares Surge Pre-Bell	22-12-14	MT
Investors Remain Sidelined in Premarket Trading Ahead of Fed Decision Wednesday	22-12-14	MT
Top Premarket Gainers	22-12-14	MT
North American Morning Briefing : Investors Wary Ahead of Fed, Powell	22-12-14	DJ
GRI Bio, Inc. entered into a definitive agreement to acquire Vallon Pharmaceuticals, Inc. from group of shareholders for $49 million in a reverse merger transaction.	22-12-12	CI
Vallon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
Vallon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-07-28	CI
Vallon Pharmaceuticals, Inc. Announces Board Changes	22-05-18	CI
Vallon Pharmaceuticals to Raise $3.9 Million in Registered Direct Offering of Common Shares	22-05-13	MT

Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel abuse-deterrent medications for central nervous system (CNS) disorders. Its technology is designed to resist manipulation for snorting and provide barriers to injection. The Company's lead investigational product candidate, Abuse-Deterrent Amphetamine Immediate-Release (ADAIR), an abuse-deterrent formulation of immediate release (IR) dextroamphetamine in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. ADAIR is designed to deter attempts to crush and snort and provides barriers to injection. In addition to ADAIR, the Company's second product candidate, ADMIR, an abuse deterrent formulation of methylphenidate (Ritalin), for the treatment of ADHD.

Sector

More about the company

Income Statement Evolution

More financial data

GRI BIOPAR

Equities

GRI

US3622AW1069

Vallon Pharmaceuticals, Inc. Announces Appointment of Meenu Karson to Board of Directors

Latest news about GRI BIOPAR

Chart GRI BIOPAR

Company Profile

Income Statement Evolution